# PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

> **NCT04347954** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 47 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Povidone-Iodine 2%
- **DRUG:** Povidone-Iodine 0.5%
- **DRUG:** Isotonic saline 0.9%

## Key facts

- **NCT ID:** NCT04347954
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-15
- **Primary completion:** 2020-12-13
- **Final completion:** 2020-12-13
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04347954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04347954, "PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04347954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*